Classement en actions
#16324
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Prix de l'action
$0.94180721
Capitalisation boursière
$22.26M
Changement (1 jour)
0.38%
Changement (1 an)
-14.35%
Échange Valbiotis SA (ALVAL)
Le prix ALVAL avec la capitalisation boursière de B
Capitalisation boursière de Valbiotis SA(ALVAL)
Capitalisation boursière: $22.26M
En July 2026, Valbiotis SA a une capitalisation boursière de $22.26M. Cela fait de Valbiotis SA la 16324th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Valbiotis SA du 2017 au 2026
ALVAL par rapport au top 5 des plus populaires stocks
| Prix pour ALVAL |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.130T
|
+23,040,964.32%
|
|
|
|
|
$4.624T
|
+20,770,336.50%
|
|
|
|
|
$4.348T
|
+19,529,650.77%
|
|
|
|
|
$2.859T
|
+12,842,806.05%
|
|
|
|
|
$2.662T
|
+11,957,316.93%
|
